Neoral® is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Neoral® has been used in combination with azathioprine and corticosteroids. Food and Drug Administration (FDA) has approved their AB-rated generic equivalent of Novartis Pharmaceuticals’ Neoral, the biggest selling softgel immunosuppressive for organ transplant recipients.
Neoral is mroe expensive than the generic version. There are reports that find no difference in the success of switching form IV to oral generic cyclosporine. This was confirmed by a randomized study.
Talaulikar GS, Gallagher MP, Carney GM, Jadeer AA, Falk MC, Hiremagalur B. Switchover to generic cyclosporine in stable renal transplant recipients: a single unit experience.Nephrology (Carlton). 2004 Dec;9(6):418-21.
Hibberd AD, Trevillian PR, Roger SD, Wlodarczyk JH, Stein AM, Bohringer EG, Milson-Hawke SM Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients.Transplantation. 2006 Mar 15;81(5):711-7.